Page last updated: 2024-12-08

2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxylic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID519874
CHEMBL ID606685
CHEBI ID187886
MeSH IDM0100885

Synonyms (22)

Synonym
ccris 4554
3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yloxy
3-carboxy-2,2,5,5-tetramethylpyrrolidine-1-oxyl
3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy
brn 4136411
2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxylic acid
2,2,5,5-tetramethyl-3-carboxypyrrolidinooxy
einecs 218-448-2
3-carboxy-2,2,5,5-tetramethyl-1-pyrollidinyloxy
2154-68-9
3-carboxy-proxyl, 98%
3-carboxy-2,2,5,5-tetramethylpyrrolidine 1-oxyl
CHEMBL606685
CHEBI:187886
AKOS005458797
STK524937
(3-carboxy-2,2,5,5-tetramethylpyrrolidin-1-yl)oxidanyl
3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxide
FT-0615286
W-200382
3-carboxy-2,2,5,5-tetramethylpyrrolidine 1-oxyl, free radical [spin label]
DTXSID60944153

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The acute LD50 doses in rats for PCA and TES are 15."( Nitroxyl spin label contrast enhancers for magnetic resonance imaging. Studies of acute toxicity and mutagenesis.
Afzal, V; Brasch, RC; Nitecki, DE; Wolff, S,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Nitroxides (10 mM) were added 10 min prior to radiation exposure and full radiation dose-response curves were determined."( Identification of nitroxide radioprotectors.
DeGraff, W; Gamson, J; Hahn, SM; Krishna, CM; Liebmann, J; Mitchell, JB; Samuni, A; Venzon, D; Wilson, L, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aminoxylsRadicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group.
pyrrolidinecarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID216901Mean surviving fraction of V79 cells following a 12-Gy dose of radiation; Not tested1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
AID216890Mean surviving fraction of V79 cells following a 1-h exposure to H2O2.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (28.13)18.7374
1990's17 (53.13)18.2507
2000's3 (9.38)29.6817
2010's2 (6.25)24.3611
2020's1 (3.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.33 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (8.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]